What Are BMY’s Neuroscience and Immuno-Science Drugs?

How Did Bristol-Myers Squibb Fare in 2Q16? PART 7 OF 8 By Mike Benson  | Aug 19, 2016 5:04 pm EDT Neuroscience and immuno-science segments Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 94% in 2Q16, while the immuno-science segment sales improved ~28% in 2Q16 as compared to 2Q15. The neuroscience segment is represented by the drug Abilify, while the immuno-science segment is represented by the drug Orencia. Abilify   Abilify is an antipsychotic agent used in the treatment of schizophrenia and major depressive disorders and is a part of the company’s alliance with Otsuka Pharmaceutical. Following the loss of exclusivity in the US markets, Abilify revenues have fallen by over 67% in 2Q16. The company had lost exclusivity for Abilify in the European markets in 2014, which impacted the…


Link to Full Article: What Are BMY’s Neuroscience and Immuno-Science Drugs?

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!